Drug intelligence / Profile preview

XtraLast

Development stage: Unknown
Lead developer: World Pharmatech
Modality: Small Molecules

Overview

XtraLast is an oral male sexual health dietary supplement developed by World Pharmaceutical Technology and positioned as a holistic alternative to prescription erectile dysfunction products. It is a proprietary multi-ingredient nutraceutical formulation composed of 16 clinically tested ingredients, including 13 herbal extracts, and is intended to support male sexual performance, including erectile dysfunction-related symptoms, by promoting normal circulation and supporting blood flow, energy, stamina, and sexual desire. It is best characterized as a multi-ingredient herbal small-molecule supplement rather than a pharmaceutical drug or biologic, and no single defined active pharmaceutical ingredient or validated molecular target has been established from the provided information.

Brand names: XtraLast

Beyond the preview

Go deeper on XtraLast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XtraLast.

Explore the full profile